TrialThe lancet. HIV2019

Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.

Takara L Stanley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.